Citations

Clear

32 citation(s) found for "Topilsky, Yan".

Prognostic impact of combined non-severe aortic stenosis and mitral regurgitation on clinical outcomes: a single-centre retrospective study
Granot, Yoav , Sapir, Orly Ran , Laufer‐Perl, Michal , Viskin, Dana , Banai, Shmuel , Topilsky, Yan , Havakuk, Ofer , Topilsky, Yan , Havakuk, Ofer

Mayo Clinic

BMJ Open | March 29, 2024 | Volume: 14 | Issue: 3 | Pages: e080914

10.1136/bmjopen-2023-080914 | PMID 38553077 Get It

Objectives Though the concomitant occurrence of non-severe aortic stenosis (AS) and mitral regurgitation (MR) is highly prevalent, there are limited data to guide clinical decision-making in this condition. Here, we attempt to determine an aortic valve area (AVA) cut-off value associated with worse clinical outcomes in patients with combined non-severe AS and MR. Methods Single-centre, retrospective analysis of consecutive patients who underwent echocardiography examination between 2010 and 2021 with evidence of combined non-severe AS and MR. We excluded patients with ≥moderate aortic valve regurgitation or mitral stenosis, as well as patients who underwent any aortic or mitral intervention either prior or following our assessment (n=372). Results The final cohort consisted of 2933 patients with non-severe AS, 506 of them with >mild MR. Patients with both pathologies had lower cardiac output and worse diastolic function. Patients with an AVA ≤1.35 cm² in the presence of >mild MR had the highest rates of heart failure (HF) hospitalisations (HR 3.1, IQR 2.4–4, p<0.001) or mortality (HR 2, IQR 1.8–2.4, p<0.001), which remained significant after adjusting for clinical and echocardiographic parameters. Conclusion Patients with combined non-severe AS and MR have a higher rate of HF hospitalisations and mortality. An AVA≤1.35 cm² in the presence of >mild MR is associated with worse clinical outcomes.
TRI-SCORE and benefit of intervention in patients with severe tricuspid regurgitation
Dreyfus, Julien , Galloo, Xavier , Heitzinger, Gregor , Benfari, Giovanni , Kresoja, Karl-Patrick, Juarez-Casso, Fernando M. , Omran, Hazem , Russo, Giulio , Topilsky, Yan , Weber, Marcel, Sala, Alessandra , Eixerés‐Esteve, Andrea , Riant, Elisabeth , Donal, Erwan , Hausleiter, Jörg , Badano, Luigi P. , Coisne, Augustin , Windecker, Stephan , Zamorano, José Luis , Tang, Gilbert H L, Webb, John G. , Muraru, Denisa , Nejjari, Mohammed , Bonis, Michele De , Carnero, Manuel , Nickenig, Georg, Pfister, Roman , Tribouilloy, Christophe , Rudolph, Volker , Lurz, Philipp , Bartko, Philipp E. , Messika–Zeitoun, David , investigators, TRIGISTRY, Heitzinger, Gregor, Bohbot, Yohan, Topilsky, Yan , Weber, Marcel, Lim, Pascal , Bazire, Baptiste , Donal, Erwan, Tourneau, Thierry Le, Modine, Thomas, Doguet, Fabien , Ajmone-Marsan, N, Stolz, Lukas, Praz, Fabien, Zamorano, José Luís , Bardeleben, Ralph Stephan von, Tang, Gilbert H L, Lubos, Edith, Webb, John A., Schöfer, Joachim, Fam, Neil , Lauten, Alexander , Pedrazzini, Giovanni , Rodés‐Cabau, Josep , Gavazzoni, Mara , Flagiello, Michele, Radu, Costin , Mbaki, Yannick, Tomasi, Jacques , Sénage, Thomas , Chan, Vincent, Alessandrini, Hannes , Eyharts, Damien , Viau, F , Himbert, Dominique , Sievert, Horst, Eggenspieler, Florian , Nicol, Martin , Nickenig, Georg , Pfister, Romain, Crestanello, Juan, Maisano, Francesco, Messika-Zeitoun, David, Kresoja, Karl-Patrik , Heitzinger, Gregor , Juarez-Casso, Fernando, Omran, Hazem , Russo, Giulio , Topilsky, Yan , Nombela-Franco, Luis , Riant, Elisabeth , Donal, Erwan , Hausleiter, Jörg , Coisne, Augustin , Praz, Fabien , Windecker, Stephan , Nejjari, Mohammed , Chan, Vincent , De Bonis, Michele , Carnero-Alcazar, Manuel , Pfister, Roman , Tribouilloy, Christophe , Rudolph, Volker , Lurz, Philipp , Maisano, Francesco , Messika-Zeitoun, David , Enriquez-Sarano, Maurice , Benfari, Giovanni , Kresoja, Karl-Patrik , Taramasso, Maurizio , Bohbot, Yohann , Iliadis, Christos , Weber, Marcel , Nombela‐Franco, Luis , Iung, Bernard , Obadia, Jean‐François , Estévez‐Loureiro, Rodrigo , Tourneau, Thierry Le , Modine, Thomas , Latib, Azeem , Praz, Fabien , von Bardeleben, Ralph Stephan , Tang, Gilbert H L, Hahn, Rebecca T , Chan, Vincent , Crestanello, Juan A. , Maisano, Francesco , Bax, Jeroen J. , Enriquez‐Sarano, Maurice , investigators, TRIGISTRY, Heitzinger, Gregor, Weber, Marcel, Donal, Erwan, Tourneau, Thierry Le, Modine, Thomas, Lavie-Badie, Yoan , Habib, Gilbert , Selton‐Suty, Christine , Stolz, Lukas , Praz, Fabien, Bardeleben, Ralph Stephan von, Ruf, Tobias Friedrich , Tang, Gilbert H L, Webb, John, Michelena, Héctor I. , Solı́s, Jorge , Flagiello, Michele, Chan, Vincent, Rahmouni, Kenza , Viau, Florence, Pfister, R, Crestanello, Juan, Maisano, Francesco, Messika-Zeitoun, David

Mayo Clinic

European Heart Journal | August 24, 2023 | Volume: 45 | Issue: 8 | Pages: 586-597

10.1093/eurheartj/ehad585 | PMID 37624856 Get It

Abstract Background and aims Benefit of tricuspid regurgitation (TR) correction and timing of intervention are unclear. This study aimed to compare survival rates after surgical or transcatheter intervention to conservative management according to a TR clinical stage as assessed using the TRI-SCORE. Methods A total of 2,413 patients with severe isolated functional TR were enrolled in TRIGISTRY (1217 conservatively managed, 551 isolated tricuspid valve surgery, and 645 transcatheter valve repair). The primary endpoint was survival at 2 years. Results The TRI-SCORE was low (≤3) in 32%, intermediate (4–5) in 33%, and high (≥6) in 35%. A successful correction was achieved in 97% and 65% of patients in the surgical and transcatheter groups, respectively. Survival rates decreased with the TRI-SCORE in the three treatment groups (all P &lt; .0001). In the low TRI-SCORE category, survival rates were higher in the surgical and transcatheter groups than in the conservative management group (93%, 87%, and 79%, respectively, P = .0002). In the intermediate category, no significant difference between groups was observed overall (80%, 71%, and 71%, respectively, P = .13) but benefit of the intervention became significant when the analysis was restricted to patients with successful correction (80%, 81%, and 71%, respectively, P = .009). In the high TRI-SCORE category, survival was not different to conservative management in the surgical and successful repair group (61% and 68% vs 58%, P = .26 and P = .18 respectively). Conclusions Survival progressively decreased with the TRI-SCORE irrespective of treatment modality. Compared to conservative management, an early and successful surgical or transcatheter intervention improved 2-year survival in patients at low and, to a lower extent, intermediate TRI-SCORE, while no benefit was observed in the high TRI-SCORE category.
Factors influencing post-surgical survival in degenerative mitral regurgitation
Butcher, Steele C. , Essayagh, Benjamin , Benfari, Giovanni , Antoine, Clémence , Roussel, Jean‐Christian , Wijngaarden, Aniek Van, Tribouilloy, Christophe , Ruşinaru, Dan, Topilsky, Yan , Michelena, Héctor I. , Delgado, Victoria , Enriquez‐Sarano, Maurice , Topilsky, Yan , Benfari, Giovanni , Roussel, Jean-Christian , Tribouilloy, Christophe , Hochstadt, Aviram , Michelena, Hector I , Enriquez-Sarano, Maurice , Delgado, Victoria , Topilsky, Yan , Essayagh, Benjamin , Butcher, Steele C , Steyerberg, Ewout W. , Grigioni, Francesco , Tourneau, Thierry Le , Marsan, Nina Ajmone , Bax, Jeroen J.

Mayo Clinic

European Heart Journal | January 4, 2023 | Volume: 44 | Issue: 10 | Pages: 871-881

10.1093/eurheartj/ehad004 | PMID 36702625 Get It

Abstract Aims Indications for surgery in patients with degenerative mitral regurgitation (DMR) are increasingly liberal in all clinical guidelines but the role of secondary outcome determinants (left atrial volume index ≥60 mL/m2, atrial fibrillation, pulmonary artery systolic pressure ≥50 mmHg and moderate to severe tricuspid regurgitation) and their impact on post-operative outcome remain disputed. Whether these secondary outcome markers are just reflective of the DMR severity or intrinsically affect survival after DMR surgery is uncertain and may have critical importance in the management of patients with DMR. To address these gaps of knowledge the present study gathered a large cohort of patients with quantified DMR, accounted for the number of secondary outcome markers and examined their independent impact on survival after surgical correction of the DMR. Methods and results The Mitral Regurgitation International DAtabase-Quantitative registry includes patients with isolated DMR from centres across North America, Europe, and the Middle East. Patient enrolment extended from January 2003 to January 2020. All patients undergoing mitral valve surgery within 1 year of registry enrolment were selected. A total of 2276 patients [65 (55–73) years, 32% male] across five centres met study eligibility criteria. Over a median follow-up of 5.6 (3.6 to 8.7) years, 278 patients (12.2%) died. In a comprehensive multivariable Cox regression model adjusted for age, EuroSCORE II, symptoms, left ventricular ejection fraction (LVEF), left ventricular end-systolic diameter (LV ESD) and DMR severity, the number of secondary outcome determinants was independently associated with post-operative all-cause mortality, with adjusted hazard ratios of 1.56 [95% confidence interval (CI): 1.11–2.20, P = 0.011], 1.78 (95% CI: 1.23–2.58, P = 0.002) and 2.58 (95% CI: 1.73–3.83, P &lt; 0.0001) for patients with one, two, and three or four secondary outcome determinants, respectively. A model incorporating the number of secondary outcome determinants demonstrated a higher C-index and was significantly more concordant with post-operative mortality than models incorporating traditional Class I indications alone [the presence of symptoms (P = 0.0003), or LVEF ≤60% (P = 0.006), or LV ESD ≥40 mm (P = 0.014)], while there was no significant difference in concordance observed compared with a model that incorporated the number of Class I indications for surgery combined (P = 0.71). Conclusion In this large cohort of patients treated surgically for DMR, the presence and number of secondary outcome determinants was independently associated with post-surgical survival and demonstrated better outcome discrimination than traditional Class I indications for surgery. Randomised controlled trials are needed to determine if patients with severe DMR who demonstrate a cardiac phenotype with an increasing number of secondary outcome determinants would benefit from earlier surgery.
The MIDA-Q Mortality Risk Score: A Quantitative Prognostic Tool for the Mitral Valve Prolapse Spectrum
Essayagh, Benjamin , Benfari, Giovanni , Antoine, Clémence , Grigioni, Francesco , Tourneau, Thierry Le , Roussel, Jean‐Christian , Bax, Jeroen J. , Delgado, Victoria , Wijngaarden, Aniek Van, Tribouilloy, Christophe , Ruşinaru, Dan, Topilsky, Yan , Thapa, Prabin , Topilsky, Yan , Le Tourneau, Thierry , Marsan, Nina Ajmone , Tribouilloy, Christophe , Hochstadt, Aviram , Topilsky, Yan , Michelena, Hector I , Enriquez-Sarano, Maurice , Delgado, Victoria , Bax, Jeroen J , Benfari, Giovanni , Topilsky, Yan , Essayagh, Benjamin , Grigioni, Francesco , Marsan, Nina Ajmone , Michelena, Héctor I. , Enriquez‐Sarano, Maurice

Mayo Clinic

Circulation | December 27, 2022 | Volume: 147 | Issue: 10 | Pages: 798-811

10.1161/circulationaha.122.062612 | PMID 36573420 Get It

Background: Mitral valve prolapse (MVP) is responsible for a considerable disease burden but is widely heterogeneous. The lack of a comprehensive prognostic instrument covering the entire MVP spectrum, encompassing the quantified consequent degenerative mitral regurgitation (DMR), hinders clinical management and therapeutic trials. Methods: The new Mitral Regurgitation International Database Quantitative (MIDA-Q) registry enrolled 8187 consecutive patients (ages 63±16 years, 47% women, follow-up 5.5±3.3 years) first diagnosed with isolated MVP, without or with DMR quantified prospectively (measuring effective regurgitant orifice [ERO] and regurgitant volume) in routine practice of 5 tertiary care centers from North America, Europe, and the Middle East. The MIDA-Q score ranges from 0 to 15 by accumulating guideline-based risk factors and DMR severity. Long-term survival under medical management was the primary outcome end point. Results: MVP was associated with DMR absent/mild (ERO <20 mm 2 ) in 50%, moderate (ERO 20–40 mm 2 ) in 25%, and severe or higher (ERO ≥40 mm 2 ) in 25%, with mean ERO 24±24 mm 2 , regurgitant volume 37±35 mL. Median MIDA-Q score was 4 with a wide distribution (10%–90% range, 0–9). MIDA-Q score was higher in patients with EuroScore II ≥1% versus <1% (median, 7 versus 3; P < 0.0001) but with wide overlap (10%–90% range, 4–11 versus 0–7) and mediocre correlation ( R 2 0.18). Five-year survival under medical management was strongly associated with MIDA-Q score, 97±1% with score 0, 95±1% with score 1 to 2, 82±1% with score 3 to 4, 67±1% with score 5 to 6, 60±1% with score 7 to 8, 44±1% with score 9 to 10, 35±1% with score 11 to 12, and 5±4% with MIDA-Q score ≥13, with hazard ratio 1.31 [1.29–1.33] per 1-point increment. Excess mortality with higher MIDA-Q scores persisted after adjustment for age, sex, and EuroScore II (adjusted hazard ratio, 1.13 [1.11–1.15] per 1-point increment). Subgroup analysis showed persistent association of MIDA-Q score with mortality in all possible subsets, in particular, with EuroScore II<1% (hazard ratio, 1.08 [1.02–1.14]) or ≥1% (hazard ratio, 1.11 [1.08–1.13]) and with no/mild DMR (hazard ratio, 1.14 [1.10–1.19]) or moderate/severe DMR (hazard ratio, 1.13 [1.10–1.16], all per 1-point increment with P <0.0001). Nested-model and bootstrapping analyses demonstrated incremental prognostic power of MIDA-Q score (all P <0.0001). Conclusions: This large, international cohort of isolated MVP, with prospective DMR quantification in routine practice, demonstrates the wide range of risk factor accumulation and considerable heterogeneity of outcomes after MVP diagnosis. The MIDA-Q score is strongly, independently, and incrementally associated with long-term survival after MVP diagnosis, irrespective of presentation, and is therefore a crucial prognostic instrument for risk stratification, clinical trials, and management of patients diagnosed with all forms of MVP.
Diastolic strain time as predictor for systolic dysfunction among patients with active breast cancer
Arnold, Joshua , Rosen, Roni , Sherez, Chen , Sherez, Jack, Derakhshesh, Matthew, Merdler, Ilan , Arbel, Yaron , Kapusta, Livia , Perl, Michal Laufer, Hochstadt, Aviram , Arnold, Joshua, Mor, Liat , Moshkovits, Yonatan , Rozenbaum, Zach , Topilsky, Yan

Mayo Clinic

No container title available | June 18, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.22541/au.159248886.61662950 Get It

Background: Although diastolic dysfunction is common among patients treated with cancer therapy, no clear evidence has been shown that it predicts systolic dysfunction. This study evaluated the correlation of longitudinal diastolic strain time (Dst) with the routine echocardiography diastolic parameters and to estimated its role in the early detection of cardiotoxicity among patients with active breast cancer. Methods: Data were collected as part of the Israel Cardio-Oncology Registry (ICOR), a prospective registry enrolling all adult patients referred to the cardio-oncology clinic. All patients with breast cancer, planned for Doxorubicin therapy were included. Echocardiography, including Global longitudinal systolic strain (GLS) and Dst, was assessed at baseline before chemotherapy (T1), during Doxorubicin therapy (T2) and after the completion of Doxorubicin therapy (T3). Cardiotoxicity were determined by GLS relative reduction of ≥15%. Dst was assessed as the time measured (ms) of the myocardium lengthening during diastole. =diastolic time (ms) measured. Results: Among 69 patients, 67 (97.1%) were females with a mean age 52±13years. Diastolic strain timeDst measurement was significantly associated with the standard routine diastolic parameters. Significant GLS reduction was observed in 10 (20%) patients at T3 . Both in a univariate and a multivariate analyses the change in Ds basal time from T1 to T2 emerged to be significantly associated with GLS reduction at T3 (p<0.04). Conclusions: Among breast cancer patients, Dst time showed high correlation to standard the routine diastolic echocardiography parameters. Relative reductionChange in Ds basal time emerged associated with clinically significant systolic dysfunction as measured by GLS reduction.
Excess Mortality Associated With Functional Tricuspid Regurgitation Complicating Heart Failure With Reduced Ejection Fraction
Benfari, Giovanni , Antoine, Clémence , Thapa, Prabin , Topilsky, Yan , Rossi, Andrea , Pislaru, Sorin V. , Enriquez‐Sarano, Maurice , Topilsky, Yan , Miller, Wayne L. , Pislaru, Sorin, Sabbah, Michael S. , Enriquez-Sarano, Maurice , Benfari, Giovanni , Topilsky, Yan , Michelena, Héctor I.

Mayo Clinic

Circulation | May 23, 2019 | Volume: 140 | Issue: 3 | Pages: 196-206

10.1161/circulationaha.118.038946 | PMID 31117814 Get It

Background: Functional tricuspid regurgitation (FTR) is common in heart failure with reduced ejection fraction and mostly consequent to pulmonary hypertension. However, the intrinsic clinical implications of FTR are not fully understood. Methods: The cohort of all Mayo Clinic patients from 2003 to 2011 diagnosed with heart failure stage B-C and ejection fraction<50%, with FTR grading and systolic pulmonary artery pressure estimation by Doppler echocardiography was identified and outcomes were analyzed. Patients with pacemakers/defibrillators, organic valve disease, or previous valve surgery were excluded. The primary outcome measure was overall mortality (censored at implantation of a defibrillator, ventricular assist device, or cardiac transplantation), adjusting for clinical and echocardiographic associates with mortality and major comorbidities. Results: Among 13 026 patients meeting inclusion criteria, FTR was detected in 88% (N=11 507: 33% trivial, 32% mild, 17% moderate, and 6% severe), aged 68±14 years, 35% women, ejection fraction 36±10%, systolic pulmonary artery pressure 41±14 mm Hg with 20% atrial fibrillation. Covariates independently associated with FTR included elevated systolic pulmonary artery pressure, older age, female sex, lower ejection fraction, mitral regurgitation, and atrial fibrillation (all P <0.0001). FTR was independently associated with more dyspnea, impaired kidney function, and lower cardiac output ( P <0.003 for all). For long-term outcome, higher FTR degree compared with trivial tricuspid regurgitation was independently associated with higher mortality (adjusted hazard ratios 1.09 [1.01-1.17] for mild FTR, 1.21 [1.11-1.33] for moderate FTR and 1.57 [1.39-1.78] for severe FTR); hence, 5-year survival was substantially lower with increasing severity of functional FTR, 68±1% for trivial FTR, 58±2% for mild FTR, 45±2% for moderate FTR, and 34±4% for severe FTR. Conclusions: In this large cohort of patients with heart failure with reduced ejection fraction, FTR was common and independently associated with pulmonary hypertension, atrial fibrillation, and more severe heart failure presentation. Long-term, higher FTR severity is associated with considerably worse survival, independently of baseline characteristics. Given these untoward outcomes associated with FTR in patients with heart failure with reduced ejection fraction, clinical trials should be directed at testing FTR treatment.
The unique mechanism of functional mitral regurgitation in acute myocardial infarction: a prospective dynamic 4D quantitative echocardiographic study
Kimura, Toshiyuki , Roger, Véronique L. , Watanabe, Nozomi , Barros‐Gomes, Sergio , Topilsky, Yan , Nishino, Shun , Shibata, Yoshisato , Enriquez‐Sarano, Maurice , Enriquez-Sarano, Maurice , Topilsky, Yan

Mayo Clinic

European Heart Journal - Cardiovascular Imaging | October 31, 2018 | Volume: 20 | Issue: 4 | Pages: 396-406

10.1093/ehjci/jey177 | PMID 30517693 Get It

AbstractAimsMechanisms of chronic ischaemic mitral regurgitation (IMR) are well-characterized by apically tethered leaflet caused by papillary muscles (PMs) displacement and adynamic mitral apparatus. We investigated the unique geometry and dynamics of the mitral apparatus in first acute myocardial infarction (MI) by using quantified 3D echocardiography.Methods and resultsWe prospectively performed 3D echocardiography 2.3 ± 1.8 days after first MI, in 174 matched patients with (n = 87) and without IMR (n = 87). 3D echocardiography of left ventricular (LV) volumes and of mitral apparatus dynamics throughout cardiac cycle was quantified. Similar mitral quantification was obtained at chronic post-MI stage (n = 44). Mechanistically, acute IMR was associated with larger and flatter annulus (area 9.29 ± 1.74 cm2 vs. 8.57 ± 1.94 cm2, P = 0.002, saddle shape 12.7 ± 4.5% vs. 15.0 ± 4.6%, P = 0.001), and larger tenting (length 6.36 ± 1.78 mm vs. 5.60 ± 1.55 mm, P = 0.003) but vs. chronic MI, mitral apparatus displayed smaller alterations (all P < 0.01) and annular size, PM movement remained dynamic (all P < 0.01). Specific to acute IMR, without PM apical displacement (P > 0.70), greater separation (21.7 ± 4.9 mm vs. 20.0 ± 3.4 mm, P = 0.01), and widest angulation of PM (38.4 ± 6.2° for moderate vs. 33.5 ± 7.3° for mild vs. 31.4 ± 6.3° for no-IMR, P = 0.0009) wider vs. chronic MI (P < 0.01).Conclusions3D echocardiography of patients with first MI provides insights into unique 4D dynamics of the mitral apparatus in acute IMR. Mitral apparatus remained dynamic in acute MI and distinct IMR mechanism in acute MI is not PM displacement seen in chronic IMR but separation and excess angulation of PM deforming the mitral valve, probably because of sudden-onset regional wall motion abnormality without apparent global LV remodelling. This specific mechanism should be considered in novel therapeutic strategies for IMR complicating acute MI.
Clinical presentation and outcome of tricuspid regurgitation in patients with systolic dysfunction
Topilsky, Yan , Medina‐Inojosa, José R. , Benfari, Giovanni , Vaturi, Ori, Maltais, Simon, Mankad, Sunil , Enriquez‐Sarano, Maurice , Topilsky, Yan , Inojosa, Jose Medina, Michelena, Hector, Enriquez-Sarano, Maurice , Medina-Inojosa, José R , Benfari, Giovanni , Michelena, Héctor I. , Topilsky, Yan

Mayo Clinic

European Heart Journal | July 4, 2018 | Volume: 39 | Issue: 39 | Pages: 3584-3592

10.1093/eurheartj/ehy434 | PMID 30060125 Get It

Standardized Definition of Structural Valve Degeneration for Surgical and Transcatheter Bioprosthetic Aortic Valves
Dvir, Danny , Bourguignon, Thierry , Rosenhek, Raphaël , Webb, John G. , Treede, Hendrik , Enriquez‐Sarano, Maurice , Feldman, Ted , Wijeysundera, Harindra C. , Topilsky, Yan , Aupart, Michel, Reardon, Michael J. , Szeto, Wilson Y. , Gammie, James S. , Yoganathan, Ajit P. , Arbel, Yaron , Borger, Michael A. , Simonato, Matheus , Reisman, Mark, Makkar, Raj , Abizaid, Alexandre , Dahle, Gry , Aldea, Gabriel S. , Leipsic, Jonathon , Pîbarot, Philippe , Moat, Neil, Mack, Michael J. , Leon, Martin B. , Topilsky, Yan , Sarano, Maurice E, Pibarot, Phillippe , Enriquez-Sarano, Maurice , Otto, Catherine M , Hahn, Rebecca T , Mackensen, G. Burkhard , Kornowski, Ran , McCabe, James M , Kappetein, A. Pieter , Topilsky, Yan , Reardon, Michael J , Abizaid, Alexandre

Mayo Clinic

Circulation | January 22, 2018 | Volume: 137 | Issue: 4 | Pages: 388-399

10.1161/circulationaha.117.030729 | PMID 29358344 Get It

Bioprostheses are prone to structural valve degeneration, resulting in limited long-term durability. A significant challenge when comparing the durability of different types of bioprostheses is the lack of a standardized terminology for the definition of a degenerated valve. This issue becomes especially important when we try to compare the degeneration rate of surgically inserted and transcatheter bioprosthetic valves. This document, by the VIVID (Valve-in-Valve International Data), proposes practical and standardized definitions of valve degeneration and provides recommendations for the timing of clinical and imaging follow-up assessments accordingly. Its goal is to improve the quality of research and clinical care for patients with deteriorated bioprostheses by providing objective and strict criteria that can be utilized in future clinical trials. We hope that the adoption of these criteria by both the cardiological and surgical communities will lead to improved comparability and interpretation of durability analyses.